Posts Tagged ‘WHO’

Weekly Blog Roundup August 23-27

August 27th, 2010

Happy Friday Readers! Check out what we talked about on End the Neglect this week!

  1. The Global Network got an awesome opportunity to showcase a 15 second spot on the CBS Superscreen in New York City! Check out the video and join Alyssa Milano and Text “LIFE” to 30644 to End The Neglect!
  2. Our wonderful communications/grassroots intern Linda shared her experience in  Honduras as a student volunteer working on construction projects for impovrished communities.
  3. We got a little clinical when discussing Lymphatic Filariasis in our second “Worm of the Week” installment.
  4. We got excited about the 30th anniversary of smallpox eradication!
  5. Alanna Shaikh talked sandflies and giant sores, with a great article on  leishmaniasis, a horrific neglected tropical disease threatening 350 million men, women and children in 88 countries!
  6. The Bill & Melinda Gates Foundation also had some great articles about smallpox this week, so we were excited to reprint them here for your reading pleasure!

Let’s Talk Leishmaniasis

August 26th, 2010

By: Alanna Shaikh

It was recently pointed out to me that I’ve never covered leishmaniasis in my posts. I’d hate to make an NTD extra-neglected, so I’ll look at it today. As a quick refresher, you may recall that I named it “giant sores and organ damage disease” in my very first post on this blog. It’s also known as kala-azar.

For a somewhat more formal description of leishmaniasis, we can turn to the World Health Organization (WHO). They’re just issued an information page on the disease. (Which, by the way, is good news. It will help raise the profile of this NTD and all the others as well.) The WHO would like you to know that:

Leishmaniasis is caused by protozoan parasites belonging to the genus Leishmania. The parasites are transmitted by the bite of a tiny – only 2–3 mm long – insect vector, the phlebotomine sandfly.

Photo Credit: CDC

» Read more: Let’s Talk Leishmaniasis

Smallpox is dead!

August 25th, 2010

Photo courtesy of WHO

A Google image search of “smallpox” will display photos which, to be frank, are startling and hard to look at. What’s even more shocking than the images themselves is the fact that smallpox remains the only disease to have been eradicated* from humanity.  2010 marks the 30th anniversary of the Global Commission for the Certification of Smallpox Eradication officially reporting the elimination of smallpox disease—one of the greatest triumphs in medicine and public health.

To commemorate this truly admirable feat, hundreds of global health practitioners, scientists and advocates have gathered in Rio de Janeiro, Brazil for a symposium that is aimed at sharing “lessons, legacies, and innovations” thirty years post the eradication of smallpox.

The Sabin Vaccine Institute will be live streaming the symposium here, and in addition to presentations by our President, Dr. Peter Hotez, and Executive Vice-President Dr. Ciro de Quadros, who served as the World Health Organization (WHO) Chief Epidemiologist for the Smallpox Eradication Program in Ethiopia from 1970 to 1976, the symposium will feature presentations by Dr. DA Henderson, Former Chief of the WHO Smallpox Eradication Program; Dr. Mirta Roses, Director of the Pan American Health Organization; Jeffrey Sachs, Director of the Earth Institute at Columbia University; and Dr. Tadataka Yamada, President of the Global Health Program at the Bill & Melinda Gates Foundation, among others.

» Read more: Smallpox is dead!

Latest Lancet Article Reveals: “Africa is Desperate for Praziquantel”

August 13th, 2010

 

Urine samples from school-aged children from Nérékoro in Ségou region of Mali. Three samples on right show visible haematuria, which indicates infection with S haematobium. Three samples on left are not haematuric at visual inspection but could still contain abnormal number of red blood cells. Urine cloudiness (third sample from left) is early sign of abnormality. Photo Credit: The Lancet

In an editorial in the August 13 edition of The Lancet, authors representing the Sabin Vaccine Institute, the World Health Organization (WHO) and the Imperial College of London call for increased supplies of praziquantel for the African continent.  Praziquantel is the only commercially available treatment for human schistosomiasis, a devastating neglected tropical disease (NTD) affects an estimated 200-600 million people worldwide, with the vast majority of cases occurring in Africa, and causes chronic anemia and inflammation associated with severe disability among children, adolescents and young adults. Schistosomiasis produces a disease burden that could exceed that of malaria.

NTDs are devastating, disabling and debilitating parasitic and bacterial infections that adversely affect the poorest 1.4 billion people worldwide living on $1.25 a day. Such conditions promote poverty because of their impact on child growth and development, pregnancy outcome, and worker productivity, all of which adversely impact the earning capacity of already impoverished individuals and communities.

Authors Dr. Peter Hotez (Sabin Vaccine Institute), Dr. Lorenzo Savioli (WHO), Dr. Dirk Engels (WHO) and Dr. Alan Fenwick (Imperial), emphasize that because an estimated one billion tablets are needed to treat 400 million people annually or every other year, at least 10-20 times the currently donated praziquantel is necessary to increase treatment for schistosomiasis in Africa.

The authors conclude by stating that, “… praziquantel is urgently needed for sub-Saharan Africa now, and the current failure of the global community to provide access to this essential medicine is impeding sustainable development in Africa. The shortages of praziquantel should be treated as an African humanitarian crisis.”

 Read the full article here 

 

Recent NTD Control Program Annual Meeting in Rwanda Brings Together Major Global Health Players

July 23rd, 2010
Kigali, Rwanda — The Ministry of Health, in partnership with Columbia University’s Access Project, organized the Neglected Tropical Diseases (NTDs) 2010 annual workshop, which was held at Laico Umubano Hotel on July 20, 2010. The objective of the meeting was to share the achievements accomplished by the NTD Control Program since its inception 3 years ago and to discuss the integration of the NTD Control Program strategies into existing initiatives.
The permanent secretary of the Ministry of Health, Dr. Agnes Binagwaho, launched the workshop by applauding the program’s impressive achievements over the past 3 years.
“We are happy with all the achievements in the fight against intestinal worms and bilharzias in Rwanda, but together with our stakeholders invited to this workshop, we are expecting to come up with strong program implementation strategies and discuss the feasibility of successfully integrating the program into existing initiatives” she said.
The NTD Control Program’s first activity was conducting a national assessment on the five most important NTDs in Rwanda, namely soil transmitted helminths (STHs), schistosomiasis, lymphatic filariasis and onchocerchiasis.

Reading List 6/21/2010

June 21st, 2010

New reading list to get your week started off right! Today we’re reading about the lack of attention that “silent killers” receive in the world of global health (the article mentions Dr. Peter Hotez, President of the Sabin Vaccine Institute), the Global Health Initiative’s announcement naming eight additional countries who will receive aid, the WHO declaring Malaybalay City, Bukidnon in the Philippines free from Filariasis, and experts urging the WHO to change its guidelines for clinical diagnosis of the neglected tropical disease Buruli Ulcer. Enjoy the reads!

The AIDS Funding Dilemma, Paul Webster, Miller-McCune
U.S. names eight countries to get health aid, Reuters
WHO declares province ‘Filariasis-free’, Sun.Star Cagayan de Oro
WHO Guidelines on Buruli Ulcer Need Adjustment, Science Daily

6th meeting of the Mebendazole Advisory Committee (MAC)

June 15th, 2010

This weeks marks the 6th meeting of the Mebendazole Advisory Committee (MAC), an independent group comprised of experts with a variety of science and health backgrounds. MAC is the advisory group for Children Without Worms (CWW), an organization working to reduce the burden of soil-transmitted helminth (STH) infections, which occurs amongst the poorest children living in tropical and subtropical nations. Children Without Worms has partnered with Johnson & Johnson and The Task Force for Global Health (formerly the Task Force for Child Survival and Development), both of whom have generously donated the drug Mebendazole, a treatment for worm infestations.

Approximately 20 percent of the world is either infected or at risk for STH infections. Children between the ages of 5 and 15 years old suffer the most, and make up one-third of the global STH burden. Children with chronic infections are at increased risk for physical and mental impairments, which can lead to learning disabilities and poor school performance. Children can also be affected before they are even born – infected  pregnant women are at high risk for low birth-weight babies and poor milk production. Additionally, their infants have higher rates of malnutrition and mortality. Furthermore, pregnant women who develop anemia while infected are three and a half times more likely to die in childbirth.

Photo Courtesy of http://www.who.int/wormcontrol/statistics/useful_info/en/index2.html

The most effective prevention methods for controlling chronic STH transmission include both proper sanitation management efforts and educational campaigns aimed at the use of latrines. As previously mentioned, two drugs are available to treat active STH infection, Albendazole and Mebendazole.

In 2001, the World Health Assembly passed a resolution to eliminate STH as a public health problem by regularly treating 75 percent of at risk children by 2010. Unfortunately, less than 20 percent of this population was reached with deworming treatment in 2005. This pressing global health issue must be addressed now and we need your help. To see how you can help control STH transmission, please visit the Global Network’s and CWW’s websites. Together we can control these infections, and assist in providing a better life for the bottom billion!

A Sea of Numbers – Measuring Global Health

June 14th, 2010

Photo Courtesy of http://www.christianwolff.com/Evidence_Based_Treatment.html

By: Eteena Tadjiogueu

There’s a sea of numbers and figures to sift through when trying to measure impact and need in the global health arena. If you dare, you can try to figure out a nation’s disease burden for a specific infection, the rate of mortality and/or morbidity, population size, resources and infrastructure, etc. If you can find what you’re looking for, there still remains a need to connect the dots between the various data, and often times, various sources.

The theme of the 2010 Global Health Council conference—which begins today in Washington, DC—is “Global Health: Goals & Metrics.” The conference is calling attention to a great need and opportunity for global health practitioners to collect and distribute accurate and informative figures that will impact funding for NGOs, and research and development of medications and vaccines if the need exists (which, of course, it does).

So where should you look if you’re interested in learning more about a specific global health problem? For starters, all things NTDs are found on the Global Network for Neglected Tropical Diseases’ site, in particular the interactive map holds a wealth of information on NTDs and stories from the field. If you don’t have access to an academic research system like LexisNexis, then you should check out the Public Library of Science which is an open-access (ie. free) scholarly journal that frequently features editorials from the Sabin Vaccine Institute’s President, Dr. Peter Hotez, as well as other notable scientists and researchers. Sabin.org has information on NTDs and diseases like rotavirus, HPV, and pneumococcal disease. When I’m looking for vaccine specific data I sift through the country data from the GAVI Alliance and the World Health Organization.

One of the Pneumococcal Awareness Council of Experts’ members, Hans Rosling, has created one of the most well known and visually appealing statistic aggregators. If you haven’t heard of Gapminder then I encourage you to take a look. Here you’ll find a list of indicators which come to life when you click play. Gapminder doesn’t currently have any information on NTDs, which is unfortunate, but their a step ahead of most in recognizing the great need for global health and development data and for making their “graphs” free and easy to understand.

What are some of your favorite sources for global health statistics and data?

Innovative financing for neglected diseases

May 26th, 2010

Reprinted with permission from: The Global Health Blog – a project of PubHealth.org

By: Sarah Arnquist

List of NTDs

List of NTDs

Neglected tropical diseases attracted the media spotlight this month, starting with a New York Times op-ed by Peter Hotez, president of the Sabin Vaccine Institute.

Now, Hotez and Bernard Pecoul, executive director of Drugs for Neglected Diseases initiative (DNDi), have released a “manifesto” outlining why the global community should increase financial support for NTD control, elimination efforts and research and development.

“About three-quarters of total neglected disease R&D annual spending is for HIV/AIDS, malaria, and tuberculosis, leaving only about US$600 million worldwide for all NTDs per year,” they write.

Last week, the open-access journal, PloS Medicine, hosted a debate over the best approach to tackle neglected tropical diseases. (For a quick overview read the blog post, “Neglected diseases: teach or treat?” from The Scientist.) The debate centered on whether the focus to eliminate the diseases has been overly medicalized at the expense of focusing on social determinants of disease and how future resources and investments should be best allocated to balance implementation and R&D.

The debate and dialogue are great and necessary, but calls for any additional funding, regardless of how it’s allocated, begs the question where will the money be raised.

While global health experienced a “golden age” of new financial commitments during the last decade, international development assistance for health has flat-lined. Given the plurality of funding demands, including HIV prevention and treatment, chronic diseases, trauma and injury and neglected tropical diseases, many say merely sustaining — let alone expanding — financial assistance requires new “innovate financing” models for global health.

Innovative financing examples include:

  • UNITAID — an international fund that uses revenues from taxes on airline tickets to promote lower prices and improved access to drugs, bed nets, etc.
  • Advance Market Commitments (AMCs), in which legally binding commitments to pay for new life-saving vaccines aim to stimulate faster and larger industry investments in R&D.
  • International Financing Facility (IFF) — rich country governments make long-term pledges to collateralize commercial debt financing.
  • Debt Swaps – rich country creditors write off debts owed by developing countries if they convert a portion of the debt value to disease control activities.

Sarah Arnquist is the editor of The Global Health Blog, part of PubHealth.org, a project aimed to create an online mechanism to facilitate harmonization among international health care researchers, practitioners and funders. Arnquist writes case studies on global health delivery issues and previously worked as a journalist. She has a master’s in public health from Johns Hopkins School of Public Health.

Where’s my Jetpack?

May 25th, 2010

by: Alanna Shaikh

It’s 2010, and I still don’t have a jetpack. My car sticks stubbornly to the ground instead of flying. Food is still food, not high-tech pellets. And we still haven’t eliminated Chagas disease.

 On July 4th, 2007, the World Health organization launched an effort to eliminate Chagas disease by 2010. The effort included a new network devoted to fighting Chagas, which would expand successful efforts by the Pan American Health organization (PAHO) to control the disease.

 Three years later, Chagas is far from eliminated. It is endemic in 21 countries, and over seven million people are currently infected with the disease. True, we have seven more months left in 2010, but it seems unlikely we’ll treat a million people every month this year and get this thing done.

 What I find frustrating is that we failed at something with such a clearly defined scope. This isn’t the Millennium Development Goals here. We’re not trying to dramatically change life on this planet. We were just trying to get rid of one treatable disease that’s endemic only in Mexico and South America.

 So what happened?

 Chagas doesn’t have great drugs to treat it. The two drugs that work on Chagas – Nifurtimox and Benznidazole – aren’t 100% effective. They work best in early stages of the disease – they can cure up to 80% of people of you catch the disease early. If you wait until the Chagas is chronic, the cure rate goes down to 10-20%. That means you spend a lot of time, effort, and money on treatments that don’t work. In addition to wasting health system capacity, it’s not exactly an incentive to come in and get treated. The drugs also work better on kids than on adults.

 To make matters worse, Nifurtimox and Benznidazole have unpleasant side effects. They include some digestive stuff from Nifurtimox: stomach pain, anorexia, nausea, and vomiting and some terrifying blood and skin side effects from the Benznidazole: swelling, hypersensitive skin, and anemia. Again, really not an incentive to keep taking your drugs.

 Aside from drugs, you can take a surgical approach to Chagas. Needless to say, surgery for the disease is difficult, painful, risky, and expensive. It’s not a feasible approach to seven million people, many of which are children.

 If we’re going to eliminate Chagas, we need to develop better drugs. That didn’t happen in time for 2010 eradication, but the situation is not hopeless. The Drugs for Neglected Diseases initiative is working on Chagas. They plan to develop an easier to manage children’s version of benznidazole, investigate combination therapies for Chagas treatment, and develop at least one new drug for Chagas by 2014.

 Also we’ll be able to deliver the drug house-to-house via visiting nurses wearing jetpacks.

 Seriously, though – how do we make sure that the 2014 goals actually come true? We pay attention. We hold policymakers to their promises, track the progress of the Drugs for Neglected Diseases initiative, and notice if years pass by and the number of people with Chagas is still almost eight million.  

Alanna Shaikh is an expert in health consulting, writing about global health for UN Dispatch and about international relief and development at Blood & Milk. She also serves as a frequently contributing blogger to ‘End the Neglect.”